Drug intelligence / Profile preview

penicillin + metronidazole

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Intramuscular

Overview

A combination antibiotic therapy that pairs penicillin, which targets bacterial cell walls, with metronidazole, which targets bacterial DNA. This combination demonstrates synergistic effects and is used to treat various infections including periodontal disease, human bite infections, and other anaerobic bacterial infections. The combination is particularly effective against periodontal pathogens such as *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, and *Fusobacterium nucleatum*.

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on penicillin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on penicillin + metronidazole.

Explore the full profile